Webinars

BLUEPRINT ACADEMY WEBINAR: Utility of genetic testing and application to immune-related disorders

02.10.2018

In partnership with the Autoinflammatory Alliance

The knowledge gained through genetic testing can lead to better patient outcomes. Heritable conditions are caused by mutations, or changes in the DNA of certain genes which are transmitted from parents to offspring. Genetic testing is a diagnostic tool that can help identify these disease-causing changes in a patient’s DNA, and consequently aid in the management of patient care, including the selection of the optimal treatment when available, and define the risk of disease to family members. Genetic testing has changed tremendously over the years and is now becoming integral diagnostic component in health care. This educational webinar will provide participants with an overview of genetics and genetic testing illustrated through immune-related patient case examples.

 

  • Summary of genetics, hereditary diseases, and inheritance patterns with patient examples
  • Overview of the different types of genetic testing and their corresponding benefits and challenges
  • Explanation of quality and performance in genetic testing
  • Description of the strategies which maximize diagnostic yield
  • Outline of the necessary considerations when selecting a patient’s optimal genetic test


Blueprint Academy
is an educational resource for healthcare professionals and organizations, patients and the scientific community. We publish informative and empowering content, webinars and white papers from the world of genetics. #geneticknowledge

In partnership with the Autoinflammatory Alliance

Autoinflammatory Alliance Webinar
The Autoinflammatory Alliance is a 501 (c)(3) non-profit public charity dedicated to promoting awareness, proper diagnosis and treatment, and improved care for people with autoinflammatory diseases.

 

Presented by

            Lucia Guidugli, PhD, FACMG, is a molecular geneticist at Blueprint Genetics. She has a strong experience in characterizing variants of unknown significance (VUS) through the use of standardized models. Lucia has completed her ABMGG clinical molecular genetics fellowship at the University of Chicago.

 

Last modified: 12.10.2018